CV Therapeutics presses on with cardiac stress agent
This article was originally published in Clinica
Executive Summary
Hoping to submit an US marketing application for its regadenoson (CVT-3146) cardiac perfusion imaging agent "as quickly as possible", CV Therapeutics has begun a second phase III clinical trial of the product.